Latest Biotechnology, Pharmaceutical and Healthcare News from Topix

09:25 EST 19th November 2017 | BioPortfolio

Here are the most relevant search results for "Topix" found in our extensive news archives from over 250 global news sources.

More Information about Topix on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Topix for you to read. Along with our medical data and news we also list Topix Clinical Trials, which are updated daily. BioPortfolio also has a large database of Topix Companies for you to search.

Showing News Articles 1–25 of 2,900+ from Topix

Saturday 18th November 2017

Seattle Genetics, Inc. (SGEN) COO Eric Dobmeier Sells 9,600 Shares of Stock

Seattle Genetics, Inc. COO Eric Dobmeier sold 9,600 shares of Seattle Genetics stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $57.80, for a total value of $554,880.00.

Huge discovery about fruits and veggies stuns scientists

The Centers for Disease Control and Prevention have come to the startling conclusion that just one in 10 people eat enough fruits and veggies. Take a good, hard look at your diet, because chances are, you're not getting nearly enough fruits and vegetables.

Teva Pharmaceutical Industries Limited (TEVA) Earns Neutral Rating from Mizuho

's stock had its "neutral" rating restated by investment analysts at Mizuho in a research note issued to investors on Friday, MarketBeat Ratings reports. They presently have a $12.00 price target on the stock, down from their prior price target of $15.00.

Cambridge Investment Research Advisors Inc. Sells 5,586 Shares of McKesson Corporation

Cambridge Investment Research Advisors Inc. cut its holdings in shares of McKesson Corporation by 20.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission . The firm owned 21,387 shares of the company's stock after selling 5,586 shares during the period.

U.S. biotechs can't shake October blues as investors await next moves

A late-summer bull run for biotechnology stocks that propelled them to outperform the broader market floundered after disappointing earnings and a lack of catalysts stopped the group in its tracks. The sector's 2017 rally garnered attention from generalist and momentum investors who focus more on quarterly sales and earnings than development pipelines and upcoming clinical data catalysts.

Contrasting Pacira Pharmaceuticals

Pacira Pharmaceuticals and Lannett Co are both small-cap pharmaceuticals - nec companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership. This is a summary of current ratings and target prices for Pacira Pharmaceuticals and Lannett Co, as r...

Bristol-Myers Squibb Target of Unusually High Options Trading

Bristol-Myers Squibb Company saw unusually large options trading activity on Wednesday. Traders acquired 781 put options on the stock.

Mannatech, Incorporated (MTEX) Plans Quarterly Dividend of $0.13

Mannatech, Incorporated declared a quarterly dividend on Friday, November 17th, RTT News reports. Stockholders of record on Thursday, December 7th will be given a dividend of 0.125 per share on Thursday, December 28th.

Impax Laboratories (IPXL) Getting Somewhat Favorable Press Coverage, Analysis Finds

Media coverage about Impax Laboratories has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time.

Friday 17th November 2017

Nevada refusing Pfizer demand for return of execution drugs

A Nevada prisons official said Friday the state is refusing pharmaceutical company Pfizer's demand to return a drug it manufactured and not use it in a planned lethal injection execution. Nevada received a letter Oct. 4 similar to one received by officials in Nebraska and reported by the Omaha World-Herald, Nevada Department of Corrections spokeswoman Brooke Keast said.

Trump's HHS Pick Alex Azar Is the Worst Pharma Bro of All

Nominating Alexander Azar to run Health and Human Services is like pinning a sheriff's badge on Billy the Kid. For all his polish and small-town charm, when it comes to pharmaceutical predation, the mild-mannered Azar puts blowhard "pharma bros" like Martin Shkreli to shame.

CVS may have a secret weapon against Amazon's move into...

CVS has made a number of acquisitions over the past decade, such as Caremark RX, a pharmacy benefits manager, Omnicare, a leading pharmacy services provider and Target's pharmacy and retail clinic businesses. That push puts the company on a better footing to CVS already offers this service and plans to expand it to all of its locations in 2018.

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK: A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks.

Cardinal Health, Inc. (CAH) Shares Bought by Macquarie Group Ltd.

Macquarie Group Ltd. lifted its position in Cardinal Health, Inc. by 4.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,105,374 shares of the company's stock after purchasing an additional 445,399 shares during the quarter.

Bayer AG (BAYN) Given a 105.00 Price Target at Barclays PLC

The firm presently has a "sell" rating on the healthcare company's stock. Barclays PLC's price objective would suggest a potential downside of 2.60% from the stock's previous close.

Cardinal Health's investment to stem opioid crisis welcomed as a start

Cardinal Health's announcement Thursday that it will increase its investment in opioid-abuse prevention and treatment programs was welcomed by those who might benefit. As the Dublin-based company continues to face accusations that it hasn't done enough to crack down on large shipments of addictive painkillers, it will invest $10 million through the first half of 2018 on effo...

J&J Gains Defense Verdict in First Trial Linking Talc Product to Mesothelioma

A California jury has sided with Johnson & Johnson in the first trial over whether its iconic baby powder caused a woman to get mesothelioma. Thursday's verdict came in a trial that began on Oct. 19 in Los Angeles Superior Court.

Arthur Zaske & Associates, LLC Buys Vanguard Energy, Teva Pharmaceutical Industries, ...

Investment company Arthur Zaske & Associates, LLC buys Vanguard Energy, Teva Pharmaceutical Industries, DowDuPont Inc, Capital One Financial Corp, Acadia Healthcare Co Inc, National Fuel Gas Co, SPDR S&P Oil & Gas Explor & Product, iPath Bloomberg Commodity Index Total Return ETN, BOK Financial Corp, Danaher Corp, sells BJ's Restaurants Inc, Apple Inc, Cisco Systems Inc, Qualco...

Jonathan W. Ayers Sells 18,000 Shares of IDEXX Laboratories, Inc. (IDXX) Stock

IDEXX Laboratories, Inc. CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total value of $2,764,980.00.

Greenwood Capital Associates LLC Increases Holdings in Bristol-Myers Squibb Company

Greenwood Capital Associates LLC boosted its holdings in shares of Bristol-Myers Squibb Company by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,422 shares of the biopharmaceutical company's stock after acquiring an additional 1,468 shares during the period.

Thursday 16th November 2017

Johnson & Johnson hit with $247 million verdict in hip implant trial

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants. Delivering the third straight win to patients against the companies, the jury found that the metal-on-metal hip implants were defectively designed and that the companies failed to warn consumers about t...

What We Can Learn From Teva's Q3 Report

Teva has to sell some of its businesses to raise cash for debt repayment and comply with FTC and EC regulations. On July 26th, 2017, I published a bearish report on Teva Pharmaceutical Industries , TEVA: Walking Dead? , pointing to the burden of a huge debt company undertook to finance its acquisition of Actavis Generics.

Wilmer Lawyer, Trump Pick for Trade Compliance Head, Reveals Salary, Clients

A Wilmer Cutler Pickering Hale and Dorr counsel in Washington who specializes in regulatory and government affairs plans to divest interests in six major U.S. companies if he's confirmed to lead enforcement and compliance efforts at the U.S. Commerce Department. Kessler said in his ethics agreement he would divest holdings in Bristol-Myers Squibb Co., Ford Motor Co., JPMorgan Chase & Co., ...

Walgreens Boots Alliance (WBA) versus Cardinal Health (CAH) Head-To-Head Contrast

Walgreens Boots Alliance and Cardinal Health are both large-cap drug retailers - nec companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends. Walgreens Boots Alliance has higher revenue, but lower earnings than Cardinal Health.

Trump Rails Against Drug Industry, but Turns to its Ranks to Fill Administration

President Trump has vilified the pharmaceutical industry and made bold promises to lower prescription drug prices. But when it comes to staffing the health care agencies empowered to oversee those efforts, he has turned regularly to the pharmaceutical industry.

Quick Search

News Quicklinks